Dry Age Macular Degeneration Drugs Market
According to report by IMARC Group, the report provides the key factors driving the advancement in treatment of Dry Age Macular Degeneration. The expanding geriatric population, who are more susceptible to the degradation of cells in the macula, thereby resulting in scarring of the retina, is primarily driving the market.